Devil's Claw

Also known as: Harpagophytum procumbens, Grapple plant, Harpagoside

The Kalahari root with arthritis credentials — anti-inflammatory harpagoides backed by real trials and gastric cautions.

Editorial review by the IngredientWiki Editorial Team
Updated 2026-09-26
5 sources
2 min read
Report an error

Pressed leaves, dried roots, seeds, and an amber vial — Editorial illustration

Selected standardized devil's-claw extracts have limited evidence for short-term osteoarthritis or low-back-pain symptom relief. The studies are older and extract-specific, and traditional digestive use lacks reliable clinical support.^{1, 2, 3}

Kalahari desert root; traditional African pain remedy^{1, 2, 3}
Active: iridoid glycosides, chiefly harpagoside^{1, 2, 3}
Best evidence: osteoarthritis and low back pain^{1, 2, 3}
Stimulates stomach acid; interacts with anticoagulants^{1, 2, 3}

What is Devil's Claw?

Devil's claw is named for its hooked fruit, not its temperament — though its effects are sharp enough. The tuber of this Kalahari survivor has moved from traditional African medicine into European pharmacies, where standardized extracts hold a recognized place in osteoarthritis and low back pain care. The evidence is respectable: several trials show pain relief in the same ballpark as modest NSAID doses, with fewer gastrointestinal side effects and a slower onset. The plant's other face is digestive — its bitters stimulate stomach acid, which helps some and warns off others.^{1, 4}

Where it comes from

Natural sources

Tubers of Harpagophytum procumbens, native to the Kalahari of Namibia, Botswana, and South Africa
Traditional use by San and Khoi peoples for pain and fever
Actives: harpagoside, harpagide, and related iridoids

How it's made

Standardized extracts (typically 50–100 mg harpagoside per dose); teas and tinctures also exist.

What it does in products

Benefits

Osteoarthritis pain

limited evidence

Trials suggest short-term pain and function improvement in osteoarthritis, but extract standardization, study quality, and comparisons with usual treatment limit certainty.^{2, 1}

The evidence applies to selected standardized extracts and symptom relief, not structural joint repair.

Low back pain

limited evidence

Randomized trials show meaningful reductions in non-specific low back pain, with some comparisons finding effects approaching conventional analgesics.^{3, 1}

Cochrane and NCCIH summaries describe low-quality evidence for short-term low-back-pain relief from a limited number of extract-specific trials.

Digestive support

insufficient evidence

Devil's claw has traditional use as a digestive bitter, but reliable clinical evidence for digestive disorders is lacking.^{4, 1}

A plausible bitter-taste mechanism and traditional use do not establish a patient-important digestive benefit.

Evidence scope and limitations

The review concerns standardized oral Harpagophytum extracts used for musculoskeletal symptoms; traditional digestive use is reported separately from clinical evidence.

Older trials use specific harpagoside-standardized extracts that may not match current products.
Gastrointestinal adverse effects and potential interactions matter in people with ulcers, gallstones, diabetes, or cardiovascular medicines.

Evidence last checked: 2026-09-26

Side effects & safety

Dyspepsia and increased stomach acid (uncommon)The bitters effect; avoid with ulcers or reflux.

Diarrhea and headache (uncommon)Usually mild and transient.

Safety considerations

Avoid — traditional use suggests uterine-stimulant potential.
Anticoagulants/antiplatelets — additive bleeding risk reported
Diabetes medications — additive glucose lowering possible
PPIs and antacids — opposing gastric effects
Not for: Peptic ulcer and gastritis
Not for: Gallstones (bitters stimulate bile flow)

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In supplement studies and products

Musculoskeletal trials use standardized extracts that deliver roughly 50–100 mg harpagoside daily, often reported as a much larger total extract mass. Findings apply to those preparations and do not establish a dose for unstandardized powder or tea.

^{2, 3}

Regulatory status

Sold as a dietary supplement; no FDA-approved disease claims.
Not applicable.

⁵

The anti-inflammatory chemistry

Harpagoside inhibits COX-2 and suppresses NF-kB-driven inflammation in cell and animal models — a mechanism overlapping with NSAIDs but acting through different entry points. The result in trials is a gentler, slower-onset analgesia: studies typically show benefit accumulating over 4–12 weeks rather than hours.

^{1, 4}

Extract quality matters

Meta-analyses show a pattern familiar in botanicals: standardized extracts with verified harpagoside content produce consistent results, while whole-root preparations vary. Products listing harpagoside content (e.g., 50–100 mg/day) are the ones that match the positive trial material.

^{1, 4}

Frequently asked questions

Does devil's claw work like an NSAID?

Its effects overlap in trials with modest NSAID doses, but onset is slower (weeks) and stomach irritation is less common — though it does increase stomach acid in some users.^{1, 2, 3}

How long until devil's claw helps joint pain?

Most trials show separation from placebo at 4–8 weeks; maximum benefit around 12 weeks.^{1, 2, 3}

Is devil's claw safe with blood thinners?

Caution — additive bleeding effects are reported. Discuss with your prescriber before combining.^{1, 2, 3}

The bottom line

Devil's claw may help selected musculoskeletal symptoms, but it is not a joint-repair treatment and not every extract matches the trials.

References

Nutritional approaches for musculoskeletal pain: what the science says. National Center for Complementary and Integrative Health (2025) · government guidance
Devil's claw in osteoarthritis: a systematic review. BMC Complementary and Alternative Medicine (2013) · systematic review · PMID 23659335
Herbal medicine for low-back pain. Cochrane Database of Systematic Reviews (2006) · systematic review · PMID 16856060
Biological and potential therapeutic actions of Harpagophytum procumbens: a review. Phytotherapy Research (2007) · other · PMID 17128436
Dietary Supplements. U.S. Food and Drug Administration (2025) · government guidance

Revision history

2026-09-26Replaced search-result citations with exact sources, mapped claims to evidence, and reassessed evidence strength.